GA
GALNF.US Galenica AG
- Market cap
- USD 5.28B
- P/E
- 24.4x
- P/B
- 2.90x
- ROE
- 18.8%
- Dividend yield
- 3.19%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.
Is GALNF.US undervalued?
Graham numberGALNF.US trades 77.4% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Galenica AG fundamental analysis
No fundamental analysis for Galenica AG yet.
Galenica AG stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Galenica AG
Galenica AG provides healthcare services in Switzerland and internationally. It operates through two segments, Products & Care, and Logistics & IT. The Products & Care segment operates and manages pharmacies and partner pharmacies under the Amavita, Sun Store, and Coop Vitality brands, as well as covers specialty pharmacy mediservice. This segment also offers medication for treatment of patients at home; laboratory medicine, pathology and specialized personalized diagnostic …
Full company profileGalenica AG financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Galenica AG annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 3.01B | 3.15B | 3.17B | 3.31B | 3.48B | 3.83B | 4.01B | 3.75B | 3.92B | 4.14B | 8.50B |
| Gross Profit | 734M | 319M | 303M | 372M | 349M | 351M | 374M | 451M | 1.09B | 429M | 771M |
| Operating Income | 124M | 131M | 106M | 163M | 202M | 186M | 193M | 191M | 204M | 223M | 332M |
| EBITDA | 158M | 182M | 155M | 257M | 303M | 300M | 294M | 307M | 337M | 339M | 663M |
| Net Income | 83.4M | 119M | 148M | 125M | 172M | 168M | 165M | 174M | 183M | 181M | 264M |
| EPS | 1.67 | 2.42 | 3.00 | 2.53 | 3.48 | 3.38 | 3.32 | 3.48 | 3.67 | 3.63 | 5.29 |
| Balance Sheet | |||||||||||
| Total Assets | 1.99B | 1.80B | 1.86B | 2.21B | 2.26B | 2.62B | 2.66B | 2.99B | 3.07B | 3.35B | 3.31B |
| Total Liabilities | 1.65B | 937M | 926M | 1.21B | 1.21B | 1.38B | 1.41B | 1.52B | 1.52B | 1.86B | 1.90B |
| Shareholders' Equity | 330M | 857M | 929M | 993M | 1.05B | 1.23B | 1.25B | 1.47B | 1.55B | 1.48B | 1.40B |
| Cash & Short-term Investments | 9.02M | 96.3M | 105M | 90.5M | 59.8M | 165M | 93.9M | 116M | 130M | 116M | 39.4M |
| Total Debt | 1.11B | 406M | 411M | 656M | 641M | 673M | 686M | 236M | 236M | 1.06B | 1.12B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 157M | 144M | 174M | 250M | 224M | 333M | 237M | 226M | 265M | 300M | 242M |
| Capital Expenditure | 34.9M | 28.0M | 27.0M | 33.7M | 55.7M | 60.1M | 70.4M | 76.4M | 72.4M | 27.4M | 77.2M |
| Free Cash Flow | 122M | 116M | 147M | 217M | 169M | 273M | 167M | 149M | 192M | 272M | 165M |
| Ratios | |||||||||||
| ROE | 25.3% | 13.9% | 15.9% | 12.6% | 16.4% | 13.7% | 13.3% | 11.8% | 11.8% | 12.2% | 18.8% |
| ROA | 4.2% | 6.6% | 7.9% | 5.7% | 7.6% | 6.4% | 6.2% | 5.8% | 6.0% | 5.4% | 8.0% |
| Net Profit Margin | 2.8% | 3.8% | 4.7% | 3.8% | 4.9% | 4.4% | 4.1% | 4.6% | 4.7% | 4.4% | 3.1% |
| Debt to Equity | 3.38x | 0.47x | 0.44x | 0.66x | 0.61x | 0.55x | 0.55x | 0.16x | 0.15x | 0.72x | 0.80x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Galenica AG dividends
- Dividend yield
- 3.19%
- Forward dividend
- 3.18 USD
- Payout ratio
- 63.6%
- Ex-dividend date
- Apr 23, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CHF 115M | 2.31 | 63.6% |
| 2024 | CHF 110M | 2.21 | 60.2% |
| 2023 | CHF 110M | 2.21 | 63.5% |
| 2022 | USD 104M | 2.10 | 63.2% |
| 2021 | USD 89.2M | 1.80 | 53.2% |
| 2020 | USD 89.2M | 1.80 | 51.8% |
| 2019 | USD 83.8M | 1.70 | 67.0% |
| 2018 | USD 81.1M | 1.65 | 55.0% |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Galenica AG
- Insiders 0.26%
- Institutions 52.64%
- Public & others 47.10%
- Shares outstanding 49.8M
- Free float 49.8M
Galenica AG company profile
- Company name
- Galenica AG
- Ticker
- GALNF.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Health Care Providers & Services
- Employees
- 6,623
- Fiscal year end
- December
- Address
- Untermattweg 8, Bern, Switzerland, 3027
- Phone
- 41 58 852 81 11
- Website
- galenica.com
About Galenica AG
Galenica AG provides healthcare services in Switzerland and internationally. It operates through two segments, Products & Care, and Logistics & IT. The Products & Care segment operates and manages pharmacies and partner pharmacies under the Amavita, Sun Store, and Coop Vitality brands, as well as covers specialty pharmacy mediservice. This segment also offers medication for treatment of patients at home; laboratory medicine, pathology and specialized personalized diagnostic services; and develops, markets, and sells healthcare services and products through various distribution channels. The Logistics & IT segment provides various specialized pre-wholesale services, including storage, distribution, and debt collection to pharmaceutical and healthcare companies. This segment also offers master data systems for the healthcare market; develops management solutions for the healthcare market; and publishes printed and electronic technical information on pharmaceutical products, as well as offers complete management solutions for pharmacies. In addition, it provides on-schedule delivery services to pharmacies, drugstores, doctors, hospitals, and care homes. The company was founded in 1927 and is headquartered in Bern, Switzerland.
Galenica AG management
10- Mr. Marc WernerChief Executive Officer · born 1967
- Mr. Julian FiessingerChief Financial Officer · born 1982
- Ms. Cécile MatterGroup General Counsel · born 1984
- Ms. Iris MullerChief Communications Officer · born 1983
- Ms. Arianne HaslerChief People & Culture · born 1979
- Dr. Jörg KneubühlerAdvisor · born 1960
- Dr. Thomas F. SzuranChief of Products & Home Care & Deputy CEO of Galenica Group · born 1967
- Mr. Daniele MadonnaChief of Pharmacies Category Management & Health Services · born 1977
- Mr. Andreas KochChief of Wholesale & Logistics · born 1971
- Ms. Virginie Pache JeschkaChief of Pharmacies Sales · born 1979